Enovis Co. (NYSE:ENOV) Receives $69.13 Average PT from Brokerages

Enovis Co. (NYSE:ENOV) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $69.13.

A number of analysts recently commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC decreased their price target on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI lowered their price target on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd.

Enovis Stock Performance

Shares of ENOV stock opened at $44.15 on Monday. The company has a current ratio of 2.10, a quick ratio of 1.03 and a debt-to-equity ratio of 0.40. Enovis has a 12-month low of $39.98 and a 12-month high of $65.03. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -29.43 and a beta of 1.92. The stock has a 50 day simple moving average of $44.98 and a 200-day simple moving average of $52.73.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.03. The firm had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. Enovis’s revenue was up 22.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 earnings per share. On average, equities analysts forecast that Enovis will post 2.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ENOV. Fidelis Capital Partners LLC acquired a new stake in Enovis during the 1st quarter valued at $34,000. Principal Securities Inc. purchased a new stake in Enovis during the 4th quarter worth about $41,000. Ridgewood Investments LLC acquired a new position in Enovis in the 2nd quarter valued at about $44,000. Benjamin F. Edwards & Company Inc. lifted its holdings in Enovis by 97.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock valued at $47,000 after purchasing an additional 417 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of Enovis during the 4th quarter worth about $53,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.